Runs a 36-hospital, ~6,100-bed network across 12 states plus Agilus, its diagnostics chain of 400+ labs.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 755 | 755 | 755 | 755 | 755 | 755 | 755 | 755 |
| Reserves | 5.9k | 5.4k | 5.4k | 6.5k | 6.9k | 8.2k | 8.7k | 9.1k |
| Borrowings | 1.6k | 1.5k | 1.3k | 926 | 1.2k | 2.5k | 3.2k | 3.5k |
| Other Liabilities | 2.8k | 3.2k | 4.1k | 3.9k | 4.2k | 2.0k | 2.4k | 2.5k |
| Total Liabilities | 11.0k | 10.9k | 11.5k | 12.1k | 13.0k | 13.4k | 15.0k | 15.8k |
| AssetsFixed Assets | 8.8k | 8.8k | 9.4k | 9.4k | 9.9k | 10.4k | 11.7k | 12.2k |
| CWIP | 204 | 165 | 193 | 228 | 542 | 407 | 306 | 434 |
| Investments | 175 | 186 | 104 | 210 | 230 | 169 | 220 | 243 |
| Other Assets | 1.9k | 1.7k | 1.8k | 2.2k | 2.3k | 2.4k | 2.8k | 2.9k |
| Total Assets | 11.0k | 10.9k | 11.5k | 12.1k | 13.0k | 13.4k | 15.0k | 15.8k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | -179 | 172 | 485 | 865 | 822 | 1.1k | 1.4k | 1.6k |
| Cash from Investing | -3.3k | 63 | -131 | -501 | -372 | -889 | -780 | -1.5k |
| Cash from Financing | 4.3k | -862 | -143 | -517 | -471 | -86 | -714 | 164 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -261 | 35 | 274 | 750 | 367 | 172 | 591 | 673 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (57.6×) and current (69.0×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 22.7% growth and a 58× exit, ₹952 only delivers your return if you pay ₹1,014. The price is currently baking in 21% growth.
EPS grows 22.7%/yr for 5 years, then fades to 6% over 2, exits at 58×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 22.7% | 16.93 |
| FY28 | 22.7% | 20.78 |
| FY29 | 22.7% | 25.49 |
| FY30 | 22.7% | 31.28 |
| FY31 | 22.7% | 38.38 |
| FY32 | 14.3% ·fade | 43.89 |
| FY33 | 6.0% ·fade | 46.52 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.